Group 1: Research and Development - The company currently has no products included in the national centralized procurement list [2] - Future R&D will focus on original traditional Chinese medicine products and chemical generic drugs, including the development of Guo Liu Wei An capsules and Oseltamivir phosphate capsules [2] - The company will also conduct secondary R&D on existing exclusive traditional Chinese medicine products, such as Dongfang Weiyao capsules and Qingchang Tongbian capsules, to explore new indications [2] Group 2: Investment Projects - The company's fundraising projects are progressing as planned, with the production application for Celecoxib capsules and Vildagliptin tablets submitted, and clinical approval obtained for Guo Liu Wei An capsules [3] Group 3: Shareholding and Control - The controlling shareholder, Tang Xian, directly holds 22.47% of the company's shares and indirectly controls an additional 1.45% through a partnership, totaling 23.92% [3] - Any future plans for shareholding increases will be disclosed in accordance with regulations [3]
梓橦宫(832566) - 关于接待机构投资者调研情况的公告